C4 Therapeutics bumps Andrew Phillips to CEO; Milind Deshpande exits Achillion; Leena Gandhi to head up I/O at Eli Lilly
→ Andrew Phillips has been diving deep into the biotech side of things ever since he left the academia to join C4 Therapeutics — he started off leading the scientific efforts but soon after assumed corporate and management duties as president. Now, he’s taking another step up to become CEO of the protein degradation biotech. That leaves his previous CSO position available for Stewart Fisher, formerly C4T’s head of discovery, to fill. Like Phillips, he had a brief stint at the Broad Institute before joining the Watertown, MA-based biotech; but unlike the new CEO, who was a professor at Yale, Fisher worked at AstraZeneca for more than 10 years. Together, they are expected to build on the targeted protein degradation platform and alliances they’ve established to realize C4T’s potential in areas like cancer, infectious disease and autoimmune disorders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.